Dow Jones Falls Sharply Due to Novartis' Failed Drug Trials
The Dow Jones Industrial Average was significantly impacted on Tuesday due to a sharp decline in Amgen's stock, which fell about 6% following disappointing news from Swiss pharmaceutical company Novartis. The drop came after Novartis announced that its late-stage trial for pelacarsen, an experimental cardiovascular drug targeting lipoprotein(a), did not meet its primary endpoint. This setback also affected smaller companies like NewAmsterdam Pharma and Dyne Therapeutics, which saw their shares fall by 10% and a quarter of their value respectively in premarket trading. Novartis' stock dropped further on Tuesday after additional bad news about another drug trial for myotonic dystrophy type 1. The price-weighted nature of the Dow means that high-priced stocks like Amgen have a larger influence, contributing to its steeper decline compared to broader indices such as the S&P 500.
Tickers: $AMGN $DYN $NAMS $NVS
Topics: Amgen clinical trial failure Dow Jones Novartis pharmaceuticals